The latest results of the EAST-AFNET 4 study will be presented at this year’s EHRA congress 2022:
Late Breaking Clinical Trials II
Atrial fibrillation – News on ablation and sex differences
Monday, 4th of April 2022 | 6:15 pm – 7:15 pm (CEST), Room 1
Session chaired by Tatjana Potpara
More information
Early rhythm control is useful in patients with atrial fibrillation regardless of the AF pattern. Patients with first diagnosed atrial fibrillation benefit from early rhythm control therapy comparably to patients with paroxysmal or persistent AF. This is the result of a subgroup analysis of the EAST – AFNET 4 trial that was presented by Professor Andreas Goette, St. Vincenz Hospital Paderborn, at the American Heart Association (AHA) congress on 14.11.2021 in Boston [1].
Asymptomatic patients with atrial fibrillation (AF) benefit from early rhythm control therapy comparably to symptomatic patients. This is the result of a subgroup analysis of the EAST – AFNET 4 trial that was presented by Professor Stephan Willems, Asklepios Hospital St. Georg, Hamburg, at the annual congress of the European Society of Cardiology (ESC) on 27.08.2021 [1] and published in the European Heart Journal [2].
The latest results of the EAST – AFNET 4 study will be presented at this year’s ESC Congress 2021 (streamed live):
Late Breaking Science in Arrhythmias
Benefit of early rhythm control therapy in patients with asymptomatic AF -insights from EAST-AFNET 4
Friday, 27th of August 2021 | 10.30am – 11:15am (CEST)
Presented by Prof. Dr. Stephan Willems
Die neuesten Ergebnisse der EAST-AFNET 4 Studie werden auf dem diesjährigen ESC Congress 2021 als Live-Stream präsentiert:
Late Breaking Science in Arrhythmias
Benefit of early rhythm control therapy in patients with asymptomatic AF -insights from EAST-AFNET 4
27.08.2021 | 10:30 – 11:15 Uhr (CEST)
Präsentiert von Prof. Dr. Stephan Willems
A subgroup analysis of the EAST – AFNET 4 study population revealed: Early initiation of rhythm control therapy is associated with clinical benefit in patients with heart failure and recently diagnosed atrial fibrillation. The new findings were presented by Dr. Andreas Rillig, UKE Hamburg, at the HRS congress on 30.07.2021 [1], [2].
The latest results of the EAST – AFNET 4 study will be presented at this year’s HRS in Boston.
Early Rhythm Control Therapy In Patients With Atrial Fibrillation And Heart Failure (PD Dr. Andreas Rillig)
Live-Stream from the Heart Rhythm Society (HRS 2021), Boston, USA.
Friday, 30 July 2021
10:45am – 10:53am Eastern time / 4:45pm – 4:53pm CEST
More information
Early Rhythm Control for the Treatment of Atrial Fibrillation (Prof. Dr. Paulus Kirchhof)
Live-Stream from the Heart Rhythm Society (HRS 2021), Boston, USA.
Friday, 30 July 2021
1:30pm – 2:30pm Eastern time / 7:30pm – 8:30pm CEST
More information
The latest results of the EAST – AFNET 4 study will be presented at this year’s HRS in Boston.
Early Rhythm Control Therapy In Patients With Atrial Fibrillation And Heart Failure (PD Dr. Andreas Rillig)
Live-Stream from the Heart Rhythm Society (HRS 2021), Boston, USA.
Friday, 30 July 2021
10:45am – 10:53am Eastern time / 4:45pm – 4:53pm CEST
The desing paper of the AFFECT-EU project “Digital, risk-based screening for atrial fibrillation in the EU” has recently been published in the European Heart Journal.
The paper can be accessed here.
Our publication of the EAST-AFNET 4 results in the New England Journal of Medicine “Early Rhythm-Control Therapy in Patients with Atrial Fibrillation“ was read over 90.000 (and cited 48) times across all 5 continents. Two “Letters to the Editor” including the answers of the authors were recently released. Please read.
